Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial, Multicentre, Opened Label Evaluating the Pharmacokinetics and the Safety and Toxicity of the Tenofovir-Emtricitabine Combination in Pregnant Women and Infants in Africa and Asia.

Trial Profile

Phase II Trial, Multicentre, Opened Label Evaluating the Pharmacokinetics and the Safety and Toxicity of the Tenofovir-Emtricitabine Combination in Pregnant Women and Infants in Africa and Asia.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Dec 2011

At a glance

  • Drugs Emtricitabine; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Acronyms TEmAA
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 02 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 May 2009 Additional trial acronym TEmAA identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top